TnAcity: A phase 2/3 randomized study of weekly nab-paclitaxel in combination with either gemcitabine or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast cancer

Category Primary study
JournalCancer Research
Year 2013
This article has no abstract
Epistemonikos ID: db8771594d1627e60103fd095edd874d706319bc
First added on: Feb 06, 2025